Ken Griffin’s Artiva Biotherapeutics ARTV Stock Holding History

Ken Griffin’s Portfolio ARTV Stock Details ARTV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$102K	Buy	+15,870	New	+$78.5K	﹤0.01%	12005
2025 Q4	–	Sell	-798,397	Closed	-$2.29M	–	14393
2025 Q3	$2.29M	Buy	798,397 +644,658	+419%	+$1.72M	﹤0.01%	5804
2025 Q2	$232K	Buy	153,739 +8,650	+6%	+$18.2K	﹤0.01%	10376
2025 Q1	$435K	Buy	145,089 +41,454	+40%	+$224K	﹤0.01%	8782
2024 Q4	$992K	Hold	103,635	–	–	﹤0.01%	7040
2024 Q3	$1.52M	Buy	+103,635	New	+$1.2M	﹤0.01%	6025

Other funds holding ARTV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

RCM

Revelation Capital Management Sausalito, California $67.4M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

Ken Griffin's ARTV Position: Q1 2026 in Review

Ken Griffin opened a new position in Artiva Biotherapeutics (ARTV) in Q1 2026: 15,870 shares worth $102K. The stake represents ﹤0.01% of the portfolio and ranks #12005 among its holdings. This is a return to the name: Ken Griffin previously reported a position in ARTV as recently as Q3 2025.

Ken Griffin first reported a position in ARTV in Q3 2024 and has held it in 6 quarters since. The position peaked at $2.29M in Q3 2025. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

Ken Griffin held 15,870 shares of Artiva Biotherapeutics worth $102K as of Q1 2026.
Artiva Biotherapeutics was a new Ken Griffin position in Q1 2026.
Artiva Biotherapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #12005 holding.
Ken Griffin first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 6 quarters since.
Ken Griffin's Artiva Biotherapeutics position peaked at $2.29M in Q3 2025.
40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.